Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

Launched by ZHEJIANG CANCER HOSPITAL · Jun 17, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment approach for patients with early-stage liver cancer, specifically those at high risk of their cancer coming back after surgery. The treatment combines three different therapies: Lenvatinib, Tislelizumab, and TACE (transarterial chemoembolization). The goal is to see how effective this combination is in shrinking tumors before surgery and to find out if it is safe for patients.

To be eligible for this trial, participants need to be between 18 and 75 years old, have a confirmed diagnosis of liver cancer, and meet certain health criteria, including having well-functioning organs and no previous treatments for their cancer. Participants can expect to receive the study treatment and will be closely monitored for how well the treatment works and any side effects. It’s important to note that this trial is currently recruiting participants, and those interested should discuss it with their healthcare provider to see if they qualify.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged 18-75 years old (inclusive);
• • 2. HCC is confirmed by preoperative pathological examination or meet the criterion of diagnosis and treatment norms of primary HCC issued by health commission, PRC. No prior systemic chemotherapy, immunotherapy, targeted therapy, or other anti-tumor treatments for HCC;
• • 3. Patients with CNLC IB or IIA stage tumors before surgery and meeting the following conditions: radiological evaluation shows narrow or none surgical margins, and preoperative tumor markers AFP+PIVKA is greater than 1600.
• • 4. ECOG score of 0 before the first administration of the study drug;
• • 5. Child-Pugh scores is 5-6 points and liver function is grade A;
• • 6. Expected survival time of at least 16 weeks;
• • 7. Pre-administration organ function levels meet the requirements and are tolerant of surgery. The functional indicators of important organs meet the following requirements: hemoglobin ≥90g/L, neutrophil count ≥1.5×10⁹/L, platelet count ≥100×10⁹/L; aspartate aminotransferase or alanine aminotransferase ≤5 times the upper limit of normal (ULN), alkaline phosphatase ≤2.5 ULN, serum albumin ≥30g/L; serum creatinine \<1.5 ULN; international normalized ratio (INR) ≤2 or prothrombin time (PT) within the upper limit of normal range ≤6 seconds; serum creatinine ≤1.5 ULN, creatinine clearance rate ≥60 mL/min.
• • 8. Male and female participants of childbearing potential must agree to use effective contraception throughout the study period;
• • 9. Sign an informed consent form and agree to provide previously stored tumor tissue specimens or fresh biopsy specimens of the tumor lesion.
• Exclusion Criteria:
• • 1. Pathologically diagnosed as non-hepatocellular carcinoma;
• • 2. Previously received anti-tumor treatments such as chemotherapy, radiotherapy, radiofrequency ablation, intervention, targeted therapy, immunotherapy or surgical treatment for liver cancer (excluding previous non-tumor-related surgery or diagnostic biopsy);
• • 3. CNLC stage is IA, IIB or worse.
• • 4. Viral load limited to hepatitis B virus (HBV) DNA\>2000 copies/ml, hepatitis C virus (HCV) RNA\>1000;
• • 5. Long-term steroid users who require long-term systemic steroid therapy (equivalent to \>10 mg of prednisone per day) or any other form of immunosuppressive treatment;
• • 6. Significant clinical bleeding or bleeding tendency within 3 months before enrollment or currently undergoing thrombolysis or anticoagulation treatment;
• • 7. Complete intestinal obstruction and incomplete intestinal obstruction requiring treatment, but patients who have had obstruction relieved by fistula or stent placement can be enrolled;
• • 8. Active severe clinical infection (\> grade 2, NCI-CTCAE version 5.0), including active tuberculosis; history of active tuberculosis infection for more than 1 year before enrollment, not treated with regular anti-tuberculosis treatment or tuberculosis still in the active period; active known or suspected autoimmune disease;
• • 9. Uncontrolled diabetes (fasting blood glucose ≥10 mmol/L), severe lung disease (such as acute pulmonary disease, pulmonary fibrosis that affects lung function, interstitial lung disease. Excluding recovered radiation pneumonitis);
• • 10. Clinically significant cardiovascular disease; hypertension which cannot be well controlled by anti-hypertensive drugs (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg);
• • 11. Patients undergoing renal replacement therapy;
• • 12. History of other malignant tumors within the past 5 years. Excluding cured basal cell carcinoma or cervical intraepithelial neoplasia;
• • 13. Other patients who are expected to be unable to tolerate surgical treatment;
• • 14. Patients who have had allergic reactions to any component of the study drug;
• • 15. Presence of alcohol dependence, mental illness, pregnancy (or lactation) or other conditions that are not suitable for clinical trials.